Wegovy (Semaglutide) Injections

Wegovy (semaglutide 2.4mg) is a weekly injectable GLP-1 receptor agonist that reduces appetite, slows gastric emptying and promotes significant weight loss — averaging 15% of body weight in clinical trials. It is now one of the most effective non-surgical weight loss medications available.

Treatment is supervised by our obesity medicine specialist, who guides dose titration, monitors for side effects and coordinates with other weight management interventions. Wegovy is a tool within a comprehensive programme — not a standalone solution.

Key Benefits

• Average 15% body weight reduction in clinical trials
• Once-weekly self-injection with auto-injector pen
• Also improves blood sugar, blood pressure and cardiovascular risk
• Medically supervised with regular monitoring

Is This Treatment Right For You?

• Adults with BMI ≥30, or ≥27 with weight-related health conditions
• Patients who have not achieved adequate results with diet and exercise alone
• Those seeking a non-surgical medical approach to weight management

What to Expect

Recovery & Aftercare

No procedural recovery; nausea is the most common side effect, typically resolving over 2–4 weeks.

Frequently Asked Questions